Modulation of Immune Cells as a Therapy for Cutaneous Lupus Erythematosus

Jorge A. Soto; Felipe Melo-González; Claudia A. Riedel; Susan M. Bueno; Alexis M. Kalergis

doi:10.3390/ijms231810706

Modulation of Immune Cells as a Therapy for Cutaneous Lupus Erythematosus

Jorge A. Soto, Felipe Melo-González, Claudia A. Riedel, Susan M. Bueno, Alexis M. Kalergis

Research output: Contribution to journal › Review article › peer-review

1 Citation (Scopus)

Abstract

Cutaneous lupus erythematosus (CLE) is an autoimmune disorder like systemic lupus erythematosus (SLE). Both SLE and CLE characterize autoantibody secretion and immune cell recruitment. In particular, CLE can be divided into three more frequent types, varying in the severity of the skin lesions they present. The role of type I IFN was shown to be one of the leading causes of the development of this pathology in the skin. Different treatments have been developed and tested against these different variants of CLE to decrease the increasing levels of CLE in humans. In this article, a literature revision discussing the similarities between SLE and CLE is carried out. In addition, new advances in understanding the development of CLE and the leading treatments being evaluated in animal models and clinical trials are reviewed.

Original language	English
Journal	International Journal of Molecular Sciences
Volume	23
Issue number	18
DOIs	https://doi.org/10.3390/ijms231810706
Publication status	Published - 14 Sept 2022

Keywords

cutaneous lupus erythematosus
immune cells
systemic lupus erythematosus
treatments

ASJC Scopus subject areas

Catalysis
Molecular Biology
Spectroscopy
Computer Science Applications
Physical and Theoretical Chemistry
Organic Chemistry
Inorganic Chemistry

Access to Document

10.3390/ijms231810706

Cite this

@article{97bc39dde1e0461a94e84bb5c64abb63,

title = "Modulation of Immune Cells as a Therapy for Cutaneous Lupus Erythematosus",

abstract = "Cutaneous lupus erythematosus (CLE) is an autoimmune disorder like systemic lupus erythematosus (SLE). Both SLE and CLE characterize autoantibody secretion and immune cell recruitment. In particular, CLE can be divided into three more frequent types, varying in the severity of the skin lesions they present. The role of type I IFN was shown to be one of the leading causes of the development of this pathology in the skin. Different treatments have been developed and tested against these different variants of CLE to decrease the increasing levels of CLE in humans. In this article, a literature revision discussing the similarities between SLE and CLE is carried out. In addition, new advances in understanding the development of CLE and the leading treatments being evaluated in animal models and clinical trials are reviewed.",

keywords = "cutaneous lupus erythematosus, immune cells, systemic lupus erythematosus, treatments",

author = "Soto, {Jorge A.} and Felipe Melo-Gonz{\'a}lez and Riedel, {Claudia A.} and Bueno, {Susan M.} and Kalergis, {Alexis M.}",

year = "2022",

month = sep,

day = "14",

doi = "10.3390/ijms231810706",

language = "English",

volume = "23",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "18",

}

TY - JOUR

T1 - Modulation of Immune Cells as a Therapy for Cutaneous Lupus Erythematosus

AU - Soto, Jorge A.

AU - Melo-González, Felipe

AU - Riedel, Claudia A.

AU - Bueno, Susan M.

AU - Kalergis, Alexis M.

PY - 2022/9/14

Y1 - 2022/9/14

N2 - Cutaneous lupus erythematosus (CLE) is an autoimmune disorder like systemic lupus erythematosus (SLE). Both SLE and CLE characterize autoantibody secretion and immune cell recruitment. In particular, CLE can be divided into three more frequent types, varying in the severity of the skin lesions they present. The role of type I IFN was shown to be one of the leading causes of the development of this pathology in the skin. Different treatments have been developed and tested against these different variants of CLE to decrease the increasing levels of CLE in humans. In this article, a literature revision discussing the similarities between SLE and CLE is carried out. In addition, new advances in understanding the development of CLE and the leading treatments being evaluated in animal models and clinical trials are reviewed.

AB - Cutaneous lupus erythematosus (CLE) is an autoimmune disorder like systemic lupus erythematosus (SLE). Both SLE and CLE characterize autoantibody secretion and immune cell recruitment. In particular, CLE can be divided into three more frequent types, varying in the severity of the skin lesions they present. The role of type I IFN was shown to be one of the leading causes of the development of this pathology in the skin. Different treatments have been developed and tested against these different variants of CLE to decrease the increasing levels of CLE in humans. In this article, a literature revision discussing the similarities between SLE and CLE is carried out. In addition, new advances in understanding the development of CLE and the leading treatments being evaluated in animal models and clinical trials are reviewed.

KW - cutaneous lupus erythematosus

KW - immune cells

KW - systemic lupus erythematosus

KW - treatments

UR - http://www.scopus.com/inward/record.url?scp=85138401866&partnerID=8YFLogxK

U2 - 10.3390/ijms231810706

DO - 10.3390/ijms231810706

M3 - Review article

C2 - 36142624

AN - SCOPUS:85138401866

SN - 1661-6596

VL - 23

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 18

ER -

Modulation of Immune Cells as a Therapy for Cutaneous Lupus Erythematosus

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this